Hyperkalemia from preoperative non-steroidal anti-inflammatory drugs and angiotensin II receptor blockers in patients with nephropathy by Song, Ho Kyung et al.
Korean J Anesthesiol 2011 December 61(6): 533-534 
http://dx.doi.org/10.4097/kjae.2011.61.6.533  Letter's to the Editor
Hyperkalemia from preoperative non-steroidal  
anti-inflammatory drugs and angiotensin II receptor 
blockers in patients with nephropathy
Ho Kyung Song, Yeon Jang, Jin Woo Nam, and Ju-Hyun You
Department of Anesthesiology, Inchon St. Mary's Hospital, The Catholic University Medical College, Incheon, Korea
Corresponding author: Ho Kyung Song, M.D., Ph.D., Department of Anesthesiology, Inchon St. Mary's Hospital, The Catholic University Medical 
College, 665, Bupyeong-dong, Bupyeong-gu, Incheon 403-720, Korea. Tel: 82-32-280-5410, Fax: 82-32-280-5416, E-mail: genovia@catholic.ac.kr
    This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
CC
Hyperkalemia is sometimes life-threatening and is common 
in patients with severe renal insufficiency [1]. Some medications 
such as cyclooxygenase (COX-1, COX-2) inhibitors, angiotensin 
converting enzyme (ACE) inhibitors, and angiotensin II receptor 
blockers (ARBs) reduce the elimination of renal potassium 
resulting in hyperkalemia. Non-steroidal anti-inflammatory 
drugs (NSAIDs) are often prescribed as pain killers but have 
known adverse effects on kidney function. Thus, the elderly and 
patients at risk for diabetic nephropathy, long-lasting hyper-
tension, or dehydration are more susceptible to the adverse 
effects of these drugs [2]. 
An episode of decreased renal function can be underestimated 
when the signs are asymptomatic, transitory, and non-anuric. 
Recently, ARBs have been prescribed in patients with hyper-
tension to maintain appropriate renal perfusion by decreasing 
the glomerular filtration burden. ARBs protect renal and cardiac 
function by lowering oxidative stress, which is associated 
with chronic changes in the kidneys, heart, and blood vessels. 
However, ARBs decrease renal blood flow and reduce the 
elimination of potassium through the kidney under relatively 
dehydrated conditions [3] and a hypertensive state. Oral 
administration of ARBs in patients with chronic renal failure has 
resulted in serum potassium increases of up to 2 mEq/L during 
an operation. Although the patient was not suspected to have 
diabetic nephropathy because of normal creatinine clearance 
and negative urine protein, a preoperative ACE inhibitor and 
ARB prescription could lead to hyperkalemia and an abnormal 
electrocardiogram during an operation [4]. Dehydration has 
been discussed as a factor in reducing renal blood flow [5]. 
Thus, chronic administration of ARBs overlapped on possible 
preoperative dehydration can affect the elimination of 
potassium resulting in hyperkalemia. 
In addition to chronic treatment with an ARB, renal side 
effects of NSAIDs are relatively common and as prevalent as 
5%. NSAIDs affect kidney function in two ways: interstitial 
nephritis due to an immunological reaction and prerenal failure 
due to reduced renal plasma flow [2]. Activating the rennin-
angiotensin system to increase glomerular filtration pressure 
is necessary to maintain sufficient filtration. This physiological 
mechanism requires sufficient local synthesis of vasodilatory 
prostaglandins (PGE2, PGI2, PGD2) to counteract the action 
of angiotensin II on vascular tone. Because NSAIDs inhibit the 
PG-mediated vasodilation of afferent arterioles and glomerular 
capillaries, renal blood flow is critically affected in those 
patients at risk [2]. 
It is also advisable for anesthesiologists to consider the 
possibility of renal dysfunction in patients at risk with medi-
cation even though there is little chance to identify abnormal 
signs or abnormal laboratory nephropathy findings. It is more 
important to perform careful monitoring preoperatively and to 
evaluate renal function and effective circulatory volume.
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